Document is current
Any future updates will be listed below
-
Authors
Soares, Nayron Medeiros https://orcid.org/0000-0001-7830-8775
da Silva, Pedro Henrique Rodrigues https://orcid.org/0000-0002-0230-7474
Pereira, Gabriela Magalhães https://orcid.org/0000-0003-0284-6678
Leoni, Renata Ferranti https://orcid.org/0000-0002-4568-0746
Rieder, Carlos Roberto de Mello https://orcid.org/0000-0003-2950-7211
Alva, Thatiane Alves Pianoschi https://orcid.org/0000-0001-9552-6993
-
Funding
Funding for this research was provided by:
Michael J. Fox Foundation for Parkinson’s Research (Michael J. Fox Foundation for Parkinson’s Research)
- License Information
-
More Information
Article History
Received: 6 February 2024
Accepted: 14 August 2024
First Online: 27 August 2024
Declarations
:
: This study was carried out in compliance with the Declaration of Helsinki and the guidelines for good clinical practices (GCP), following approval from the local ethics committees of the sites participating in the Parkinson’s Progression Markers Initiative (PPMI, ). PPMI is a landmark observational clinical study that aims to identify progression biomarkers to improve PD therapy. The relevant local institutional review boards approved the PPMI protocol and written informed consent was obtained from all participants prior to inclusion. In addition, there was additional ethical approval from the Research Ethics Committee at the Universidade Federal de Ciências da Saúde de Porto Alegre Porto Alegre (UFCSPA), protocol nº 5,040,927, the location where the data were analysed.
: Not applicable.
: The authors declare no conflicts of interest.
